keyword
MENU ▼
Read by QxMD icon Read
search

Natalizumab

keyword
https://www.readbyqxmd.com/read/27910101/early-safety-and-efficacy-of-fingolimod-treatment-in-denmark
#1
A Voldsgaard, N Koch-Henriksen, M Magyari, F Sellebjerg, P S Sørensen, A B Oturai
BACKGROUND: Initiation of fingolimod treatment is associated with a transient decrease of heart rate, and atrioventricular (AV) conduction block may occur. OBJECTIVE: To evaluate the therapeutic effect and safety of fingolimod treatment in MS patients in Denmark with focus on cardiac and pulmonary side effects at treatment onset. MATERIALS & METHODS: We analysed data from the first 496 fingolimod-treated Danish patients, observed for at least 3 months...
January 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27904430/natalizumab-related-progressive-multifocal-leukoencephalopathy-immune-reconstitution-inflammatory-syndrome-a-case-report-highlighting-clinical-and-mri-features
#2
Bela Purohit, Eranga Ganewatte, Spyros S Kollias
Multiple sclerosis (MS) patients treated with natalizumab often face the uncommon but severe complication of developing progressive multifocal leukoencephalopathy (PML). PML may be further complicated by immune reconstitution inflammatory syndrome (IRIS) after the removal of the drug. Since both PML and IRIS are associated with high morbidity and mortality rates, early clinical and radiological diagnosis of these complications is of paramount importance. Here, we report a case of an adult male patient who was diagnosed with PML after receiving natalizumab therapy for 6 years for the treatment of MS...
September 2016: Malaysian Journal of Medical Sciences: MJMS
https://www.readbyqxmd.com/read/27891572/safety-concerns-and-risk-management-of-multiple-sclerosis-therapies
#3
REVIEW
P Soelberg Sorensen
Currently, more than ten drugs have been approved for treatment of relapsing-remitting multiple sclerosis (MS). Newer treatments may be more effective, but have less favorable safety record. Interferon-β preparations and glatiramer acetate treatment require frequent subcutaneous or intramuscular injections and are only moderately effective, but have very rarely life-threatening adverse effects, whereas teriflunomide and dimethyl fumarate are administered orally and have equal or better efficacy, but have more potentially severe adverse effects...
November 27, 2016: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27879549/fingolimod-use-for-the-treatment-of-multiple-sclerosis-in-a-clinical-practice-setting-in-madrid
#4
Victoria Galán Sánchez-Seco, Ignacio Casanova-Peño, Roberto Álvarez-Lafuente, Mónica Sánchez-Jiménez, Ángel García-Martínez, María Inmaculada Domínguez-Mozo, Ana María Arias-Leal, Marta García-Montojo, Rafael Arroyo-González
OBJECTIVE: To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting. METHODS: Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. Effectiveness and safety data were collected during the entire treatment of each patient. Analysis was performed for the total population and stratified according to prior treatment, sex, and age at treatment initiation...
November 22, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27878443/real-world-effectiveness-of-natalizumab-and-fingolimod-compared-with-self-injectable-drugs-in-non-responders-and-in-treatment-na%C3%A3-ve-patients-with-multiple-sclerosis
#5
Luca Prosperini, Francesco Saccà, Cinzia Cordioli, Antonio Cortese, Fabio Buttari, Simona Pontecorvo, Assunta Bianco, Serena Ruggieri, Shalom Haggiag, Vincenzo Brescia Morra, Ruggero Capra, Diego Centonze, Giancarlo Di Battista, Elisabetta Ferraro, Ada Francia, Simonetta Galgani, Claudio Gasperini, Enrico Millefiorini, Massimiliano Mirabella, Carlo Pozzilli
In this independent, multicentre post-marketing study we directly compared the effectiveness of natalizumab (NTZ), fingolimod (FNG) and self-injectable drugs (INJ), in non-responders to first immunomodulating treatment and in highly active treatment-naïve patients with multiple sclerosis. As main outcome measure we considered the proportions of patients with no evidence of disease activity (NEDA-3), defined as absence of relapses, disability worsening and radiological activity. A total of 567 non-responders to interferon beta (IFNB) or glatiramer acetate (GA) [dataset A] and 216 highly active treatment-naïves [dataset B] were followed up to 24 months from the beginning of NTZ, FNG or INJ, i...
November 22, 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27864092/successful-desensitization-to-natalizumab-using-a-1-solution-protocol
#6
Eva Pérez-Rodríguez, Miguel Ángel Hernández-Pérez, Juan Antonio Martínez-Tadeo
No abstract text is available yet for this article.
November 15, 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27862809/assessing-understanding-patients-prescribed-natalizumab-for-multiple-sclerosis-individual-risk-and-symptoms-of-progressive-multifocal-leukoencephalopathy
#7
Louise Rath, Nirosen Vijiaratnam, Olga Skibina
BACKGROUND: Natalizumab, a monoclonal antibody directed against α4 integrin, is a highly efficacious treatment commonly used in Relapsing Remitting Multiple Sclerosis (MS). Natalizumab is associated with the potentially fatal rare demyelinating opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Prognosis and disability from PML is determined by early diagnosis. Written tools are mandated in Australia and other prescribing countries with the aim to help patients understand the risks associated with treatment and ensure familiarity with the early symptoms of PML...
November 9, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27857690/interferon-beta-increases-plasma-ceramides-of-specific-chain-length-in-multiple-sclerosis-patients-unlike-fingolimod-or-natalizumab
#8
Florian M Ottenlinger, Christoph A Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin G Schmidt, Hanns Ackermann, Josef M Pfeilschifter, Heinfried H Radeke
Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate (S1P). Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 15 representative sphingolipid species by mass spectrometry in plasma from relapsing-remitting MS patients currently under fingolimod (n = 24), natalizumab (n = 16), or IFN-β (n = 18) treatment. Healthy controls (n = 21) and untreated MS patients (n = 11) served as control groups...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27844037/risk-of-relapse-after-natalizumab-withdrawal-results-from-the-french-tysedmus-cohort
#9
Caroline Papeix, Sandra Vukusic, Romain Casey, Nadine Debard, Bruno Stankoff, Serge Mrejen, Zoe Uhry, Eric Van Ganse, Anne Castot, Michel Clanet, Catherine Lubetzki, Christian Confavreux
OBJECTIVE: To assess disease activity within 12 months after natalizumab (NZ) discontinuation in a large French postmarketing cohort. METHODS: In France, patients exposed at least once to NZ were included in the TYSEDMUS observational and multicenter cohort, part of the French NZ Risk Management Plan. Clinical disease activity during the year following NZ discontinuation was assessed in this cohort. Time to first relapse after NZ stop was analyzed using Kaplan-Meier method and potentially associated factors were studied using a multivariate Cox model...
December 2016: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27829656/safety-and-efficacy-of-fingolimod-and-natalizumab-in-multiple-sclerosis-after-the-failure-of-first-line-therapy-single-center-experience-based-on-the-treatment-of-forty-four-patients
#10
Przemysław Puz, Anetta Lasek-Bal
BACKGROUND In Poland, natalizumab or fingolimod treatment can be delivered as a second-line therapy to those patients with relapsing-remitting multiple sclerosis (RRMS) who demonstrated no response to interferon or glatiramer acetate treatment for a minimum of one year. MATERIAL AND METHODS Analysis covered 44 RRMS patients switched from first- to second-line therapy. The annualized relapse rate, disability progression (assessed with Expanded Disability Status Scale, EDSS) and MRI results (new or enlarged T2 lesions and new Gd-positive lesions) before and after switching were compared...
November 10, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#11
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#12
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27817117/differences-in-t-cell-cytotoxicity-and-cell-death-mechanisms-between-progressive-multifocal-leukoencephalopathy-herpes-simplex-virus-encephalitis-and-cytomegalovirus-encephalitis
#13
Susanne Laukoter, Helmut Rauschka, Anna R Tröscher, Ulrike Köck, Etsuji Saji, Kurt Jellinger, Hans Lassmann, Jan Bauer
During the appearance of human immunodeficiency virus infection in the 1980 and the 1990s, progressive multifocal leukoencephalopathy (PML), a viral encephalitis induced by the JC virus, was the leading opportunistic brain infection. As a result of the use of modern immunomodulatory compounds such as Natalizumab and Rituximab, the number of patients with PML is once again increasing. Despite the presence of PML over decades, little is known regarding the mechanisms leading to death of infected cells and the role the immune system plays in this process...
November 5, 2016: Acta Neuropathologica
https://www.readbyqxmd.com/read/27815407/cd62l-test-at-2-years-of-natalizumab-predicts-progressive-multifocal-leukoencephalopathy
#14
Béatrice Pignolet, Nicholas Schwab, Tilman Schneider-Hohendorf, Florence Bucciarelli, Damien Biotti, Delphine Averseng-Peaureaux, Olivier Outteryck, Jean-Claude Ongagna, Jérôme de Sèze, Bruno Brochet, Jean-Christophe Ouallet, Marc Debouverie, Sophie Pittion, Gilles Defer, Nathalie Derache, Patrick Hautecoeur, Ayman Tourbah, Pierre Labauge, Giovanni Castelnovo, Pierre Clavelou, Eric Berger, Jean Pelletier, Audrey Rico, Hélène Zéphir, David Laplaud, Sandrine Wiertlewski, William Camu, Eric Thouvenot, Olivier Casez, Thibault Moreau, Agnès Fromont, Sandra Vukusic, Caroline Papeix, Patrick Vermersch, Manuel Comabella, Christine Lebrun-Frenay, Heinz Wiendl, David Brassat
No abstract text is available yet for this article.
November 4, 2016: Neurology
https://www.readbyqxmd.com/read/27812788/jc-polyomavirus-expression-and-bell-shaped-regulation-of-its-sf2-asf-suppressor-during-the-follow-up-of-multiple-sclerosis-patients-treated-with-natalizumab
#15
Elena Uleri, Gabriele Ibba, Claudia Piu, Maurizio Caocci, Stefania Leoni, Giannina Arru, Caterina Serra, GianPietro Sechi, Antonina Dolei
Natalizumab is effective against multiple sclerosis (MS), but is associated with progressive multifocal leukoencephalopathy (PML), fatal disease caused by the JCV polyomavirus. The SF2/ASF (splicing factor2/alternative splicing factor) inhibits JCV in glial cells. We wondered about SF2/ASF modulation in the blood of natalizumab-treated patients and if this could influence JCV reactivation. Therefore, we performed a longitudinal study of MS patients under natalizumab, in comparison to patients under fingolimod and to healthy blood donors...
November 3, 2016: Journal of Neurovirology
https://www.readbyqxmd.com/read/27806057/occurrence-of-anti-drug-antibodies-against-interferon-beta-and-natalizumab-in-multiple-sclerosis-a-collaborative-cohort-analysis
#16
Delphine Bachelet, Signe Hässler, Cyprien Mbogning, Jenny Link, Malin Ryner, Ryan Ramanujam, Michael Auer, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Clemens Warnke, Kathleen Ingenhoven, Dorothea Buck, Verena Grummel, Andy Lawton, Naoimh Donnellan, Agnès Hincelin-Mery, Dan Sikkema, Marc Pallardy, Bernd Kieseier, Bernard Hemmer, Hans Peter Hartung, Per Soelberg Sorensen, Florian Deisenhammer, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, Philippe Broët
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospective data from routine ADA test laboratories in Sweden, Denmark, Austria and Germany (Dusseldorf group) and from one research study in Germany (Munich group) were gathered to build a collaborative multi-cohort dataset within the framework of the ABIRISK project. A subset of 5638 interferon-beta (IFNβ)-treated and 3440 natalizumab-treated patients having data on at least the first two years of treatment were eligible for interval-censored time-to-event analysis...
2016: PloS One
https://www.readbyqxmd.com/read/27803638/disability-progression-after-switching-from-natalizumab-to-fingolimod-or-interferon-beta-glatiramer-acetate-therapies-a-narcoms-analysis
#17
Stacey S Cofield, Robert J Fox, Tuula Tyry, Amber R Salter, Denise Campagnolo
Background: Physicians must weigh the benefits against the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, especially beyond 2 years. However, disability progression associated with switching therapies versus continuing natalizumab therapy after 2 years has not been fully evaluated. Methods: In this retrospective analysis using the NARCOMS Registry, disability progression (Patient-Determined Disease Steps [PDDS] scale) and physical health-related quality of life (HRQOL) worsening (12-item Short Form Health Status Survey Physical Component Score [SF-12 PCS]) were compared between participants switching to fingolimod (n = 50) or interferon beta (IFNβ)/glatiramer acetate (GA) (n = 71) therapy and those continuing natalizumab (n = 406) after 2 years or more of treatment (median follow-up: natalizumab, 4 years; fingolimod, 4...
September 2016: International Journal of MS Care
https://www.readbyqxmd.com/read/27803063/the-role-of-%C3%AE-4-integrin-in-theiler-s-murine-encephalomyelitis-virus-tmev-induced-demyelinating-disease-an-infectious-animal-model-for-multiple-sclerosis-ms
#18
Yuta Hirano, Kunitoshi Kobayashi, Hiroki Tomiki, Yuhji Inaba, Motoki Ichikawa, Byung S Kim, Chang-Sung Koh
Natalizumab, which is an antibody against α4 integrin, has been used for the treatment of multiple sclerosis (MS). In the present study, we investigated both the role of α4 integrin and the therapeutic effect of HCA3551, a newly synthesized orally active small-molecule α4 integrin antagonist, in the development of TMEV-induced demyelinating disease (TMEV-IDD). The mRNA levels of α4 integrins were significantly up-regulated in the CNS of mice with TMEV-IDD as compared with naïve mice (*p<0.05). HCA3551 treatment in the effector phase significantly suppressed both the clinical and histological development of TMEV-IDD...
November 1, 2016: International Immunology
https://www.readbyqxmd.com/read/27800533/natalizumab-treatment-leads-to-an-increase-in-circulating-cxcr3-expressing-b-cells
#19
Maija Saraste, Tarja-Leena Penttilä, Laura Airas
OBJECTIVE: To study the effects of natalizumab treatment on subgroups of circulating peripheral blood B cell populations. METHODS: We studied the proportions and absolute numbers of CD19(+)CD20(+), CD10(+), and CD5(+) B cell populations, and determined very late activation antigen-4 and chemokine receptor CXCR3, CCR5, and CCR6 expression on B cells in the peripheral blood of 14 natalizumab-treated patients with relapsing-remitting multiple sclerosis. Five blood samples per patient were obtained longitudinally before and during the first year of treatment...
December 2016: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27799479/comparative-efficacy-of-fingolimod-vs-natalizumab-a-french-multicenter-observational-study-writeclick-editor-s-choice
#20
(no author information available yet)
No abstract text is available yet for this article.
November 1, 2016: Neurology
keyword
keyword
27292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"